![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
GSK2336805 HCV NS5A Inhibitor Demonstrates Potent Antiviral Activity in Chronic Hepatitis C (CHC) Genotype 1 Infection: Results from a First Time in Human (FTIH) Single and Repeat Dose Study
|
|
|
Reported by Jules Levin AASLD Nov 5-9 2011 SF
W Spreen1, D Wilfret1, J Bechtel1, K Adkison1, Y Lou1, L Jones1, S Willsie2, S Glass3, C Roberts1 1. Research and Development, GlaxoSmithKline, Research Triangle Park, NC, 2. PRA International, Lenexa, KS, 3. CRI Worldwide, Willingboro, NJ
![AASLD1.gif](../images/110911/110911-4/AASLD1.gif)
![AASLD2.gif](../images/110911/110911-4/AASLD2.gif)
![AASLD3.gif](../images/110911/110911-4/AASLD3.gif)
![AASLD4.gif](../images/110911/110911-4/AASLD4.gif)
![AASLD5.gif](../images/110911/110911-4/AASLD5.gif)
![AASLD6.gif](../images/110911/110911-4/AASLD6.gif)
![AASLD7.gif](../images/110911/110911-4/AASLD7.gif)
![AASLD8.gif](../images/110911/110911-4/AASLD8.gif)
![AASLD9.gif](../images/110911/110911-4/AASLD9.gif)
![AASLD10.gif](../images/110911/110911-4/AASLD10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|